A Glaucoma Division to be Launched by Entod Pharma

Entod Pharmaceuticals has announced that the company is all set to launch its GLO division to further expand its business. This one-of-a-kind ophthalmic subspeciality division is focused on the treatment of the eye condition glaucoma, which is a leading cause of irreversible blindness in India. Earlier this year, Entod Pharmaceuticals marked its presence in two major arenas. The first was the launch of its HyTek Surgical, a super-speciality ophthalmic surgical division, catering to intra-operative solutions for ophthalmic surgical needs.

The other was it's dermatological venture in collaboration with its UK sister company Entod Beauty London Ltd, under which Entod Beauty products began their sale in India. Nikkhil K Masurkar, CEO, Entod Pharmaceuticals said, "This year has been both challenging and exceptional for our business where we focussed on expanding our horizon beyond the convention. We have flourished in all the spheres that we set foot in. The latest milestone being the launch of our GLO Division is envisioned with the mission to ensure some real changes to the plight of glaucoma in our country." Anjula Masurkar, Clinical Director, Entod Pharmaceuticals commented, "This move is bound to further strengthen ophthalmology medicine in India.

Our GLO division will include some of the best quality anti-glaucoma medicines intended for promotion across the country and that too at competitor prices for patients. Over 95% of globally available anti-glaucoma molecules and therapies shall be covered through this division thereby giving access to crores of patients across then country. Furthermore our research teams are currently engaged in investigating several new glaucoma therapeutic options, that shall provide the latest treatment advances."